or Try an Advanced Search...

    Technical Analysis for ALXO - ALX Oncology Holdings Inc.

    Grade Last Price % Change Price Change
    F 1.52 -0.98% -0.02
    ALXO closed down 0.98 percent on Thursday, November 7, 2024, on 43 percent of normal volume.
    Earnings due: Nov 11
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical ALXO trend table...
    Date Alert Name Type % Chg
    20 DMA Support Bullish 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    20 DMA Support Bullish -0.98%
    Bollinger Band Squeeze Range Contraction -0.98%
    Doji - Bearish? Reversal -0.98%
    Outside Day Range Expansion -0.98%
    Up 3 Days in a Row Strength -0.98%
    Up 4 Days in a Row Strength -0.98%
    Up 5 Days in a Row Strength -0.98%
    Older End-of-Day Signals for ALXO ...

       Recent Intraday Alerts

    Alert Time
    Possible Inside Day about 5 hours ago
    Up 1% about 6 hours ago
    60 Minute Opening Range Breakout about 6 hours ago
    Down 5% about 8 hours ago
    1.5x Volume Pace about 9 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    ALXO Chart by TradingView
    Basic chart:

    Profile

    ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Clinical Medicine Solid Tumors Oncology Cancer Immunotherapy Acute Myeloid Leukemia Epidermal Growth Factor Receptor Carcinoma Myelodysplastic Syndrome Syndromes Treatment Of Myelodysplastic Syndrome

    Is ALXO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 4 ALX Oncology Announces November Investor Conference Participation
    Nov 1 ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
    Oct 10 Millennium Management LLC Reduces Stake in ALX Oncology Holdings Inc
    Sep 12 ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations
    Sep 9 ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
    Sep 4 ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
    Aug 27 Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
    Aug 9 ALX Oncology GAAP EPS of -$0.76 in-line
    Aug 8 ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
    Aug 6 ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
    See more ALXO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 17.825
    52 Week Low 1.335
    Average Volume 602,255
    200-Day Moving Average 8.46
    50-Day Moving Average 1.78
    20-Day Moving Average 1.50
    10-Day Moving Average 1.46
    Average True Range 0.13
    RSI (14) 42.86
    ADX 21.92
    +DI 18.94
    -DI 15.77
    Chandelier Exit (Long, 3 ATRs) 1.39
    Chandelier Exit (Short, 3 ATRs) 1.72
    Upper Bollinger Bands 1.62
    Lower Bollinger Band 1.38
    Percent B (%b) 0.57
    BandWidth 16.38
    MACD Line -0.10
    MACD Signal Line -0.14
    MACD Histogram 0.0383
    Fundamentals Value
    Market Cap 75.48 Million
    Num Shares 49.8 Million
    EPS -3.57
    Price-to-Earnings (P/E) Ratio -0.42
    Price-to-Sales 5906.24
    Price-to-Book 4.15
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.63
    Resistance 3 (R3) 1.63 1.58 1.61
    Resistance 2 (R2) 1.58 1.55 1.58 1.61
    Resistance 1 (R1) 1.55 1.53 1.52 1.55 1.60
    Pivot Point 1.50 1.50 1.49 1.50 1.50
    Support 1 (S1) 1.47 1.47 1.44 1.48 1.43
    Support 2 (S2) 1.42 1.45 1.42 1.42
    Support 3 (S3) 1.39 1.42 1.42
    Support 4 (S4) 1.40